<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel G Bichet, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Arginine vasopressin resistance (AVP-R), previously called nephrogenic diabetes insipidus [<a href="#rid1">1</a>], results from partial or complete resistance of the kidney to the effects of antidiuretic hormone (ADH, also known as arginine vasopressin [AVP]). As a result, patients with this disorder are not likely to have a good response to hormone administration (as <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> [dDAVP]) or to drugs that increase either the renal response to ADH or ADH secretion.</p><p>AVP-R can be hereditary or acquired. In adults, a concentrating defect severe enough to produce polyuria due to AVP-R is most often due to chronic <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> use or hypercalcemia and less frequently to other conditions that impair tubular function, such as Sjögren's disease [<a href="#rid2">2</a>]. Release of ureteral obstruction is often associated with a diuresis, but this is short lived and does not require specific therapy other than maintenance fluids. (See  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a> and  <a class="medical medical_review" href="/d/html/7174.html" rel="external">"Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis", section on 'Prognosis'</a>.)</p><p>Hereditary AVP-R, which is largely an X-linked disease, may also be seen by internists since early recognition and treatment in infancy has led to survival to adulthood [<a href="#rid3">3-5</a>]. In addition, affected women may be carriers with few or no symptoms until pregnancy or other stress.</p><p>In infants with hereditary AVP-R, treatment is aimed at minimizing the polyuria and avoiding hypernatremia and volume depletion. In adults, therapy is usually aimed at correcting the underlying disorder or discontinuing an offending drug. In hypercalcemic patients, for example, normalization of the plasma calcium concentration usually leads to amelioration of polyuria. By contrast, lithium-induced AVP-R may be irreversible if the patient already has severe tubular injury and a marked concentrating defect [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/2358.html" rel="external">"Renal toxicity of lithium"</a>.)</p><p>The approach to the treatment of polyuria in patients with AVP-R will be reviewed here. The causes of AVP-R, the diagnostic approach to polyuria, and the treatment of arginine vasopressin deficiency (AVP-D, previously known as central diabetes insipidus) are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2381.html" rel="external">"Evaluation of patients with polyuria"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2313.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The urine output in patients with AVP-R can be lowered with a low-salt, low-normal protein diet, diuretics, and nonsteroidal antiinflammatory drugs (NSAIDs). In infants, early recognition is of immediate clinical significance because treatment can avert the physical and intellectual disabilities that results from repeated episodes of dehydration and hypernatremia. (See  <a class="medical medical_review" href="/d/html/2381.html" rel="external">"Evaluation of patients with polyuria"</a>.)</p><p>In adults, the decision to undertake treatment must be based upon the individual patient's intolerance of the polyuria and polydipsia since, in almost all patients, the thirst mechanism is sufficient to maintain the plasma sodium in the high-normal range. The treatment of patients with hypernatremia is discussed separately. (See  <a class="medical medical_review" href="/d/html/2339.html" rel="external">"Treatment of hypernatremia in adults"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Special considerations in hereditary disease</span><span class="headingEndMark"> — </span>Given their inability to independently respond to increased thirst, infants and very young children should be offered water every two hours during the day and night. In severe cases, continuous gastric feeding may be required. However, the ingestion of large quantities of water may exacerbate physiologic gastroesophageal reflux in infants and toddlers, which may require treatment. Appetite and growth should be monitored closely. (See  <a class="medical medical_review" href="/d/html/5900.html" rel="external">"Management of gastroesophageal reflux disease in children and adolescents"</a>.)</p><p>The high urine flow associated with hereditary AVP-R induces dilatation of the urinary tract (hydronephrosis) and bladder in ≥50 percent of cases [<a href="#rid7">7-9</a>]. A rare complication is progressive loss of kidney function and possible end-stage kidney disease, probably related to voluntary retention of urine leading to bladder dysfunction [<a href="#rid10">10-12</a>]. These problems may also occur with other causes of massive urine volumes, most commonly seen with primary polydipsia [<a href="#rid10">10</a>].</p><p>Decreasing urine flow with the interventions discussed below [<a href="#rid13">13</a>], and frequent voiding and "double voiding" (to empty the bladder entirely), are important preventive measures. This approach should be taught to children once they are old enough, and should be continued in adulthood, to prevent severe dilatation of the urinary tract.</p><p class="headingAnchor" id="H20129240"><span class="h2">Special considerations in patients requiring intravenous fluids</span><span class="headingEndMark"> — </span>Patients, particularly children, with AVP-R who have extrarenal fluid losses (eg, diarrhea, vomiting, and fever) frequently require intravenous fluids [<a href="#rid14">14</a>]. Both <a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">5 percent dextrose in water</a> and one-quarter isotonic (0.22 percent) <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> are usually well tolerated, but a replacement fluid that has a higher osmolality than the urine (eg, one-half isotonic [0.45 percent] saline) can produce hypernatremia, even though it may have a lower osmolality as compared with plasma. As an example, a patient who has a maximal urine osmolality of 100 mosmol/kg will need to excrete 1.54 liters of urine for each liter of 0.45 percent saline received in order to excrete the osmotic load, resulting in a net loss of 0.54 liters of water. However, if hypotonic fluids are administered at a rate higher than the urine output, hyponatremia can ensue. These considerations should be taken into account in order to prevent complications in patients with AVP-R requiring intravenous fluids [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Decreased dietary solute</span><span class="headingEndMark"> — </span>When the urine osmolality is fixed, as in AVP-R, the urine output is determined by solute excretion. Suppose that the maximum urine osmolality is 150 mosmol/kg. In this setting, the daily urine volume will be 5 liters if solute excretion is in the normal range at 750 mosmol/day, but only 3 liters if solute excretion is lowered to 450 mosmol/day by dietary modification.</p><p>These observations provide the rationale for the use of a low-salt, low-protein diet to diminish the urine output in AVP-R [<a href="#rid2">2,16</a>]. The reduction in urine output will be directly proportional to the decrease in solute intake and excretion. Restriction of salt intake to ≤100 mEq/day (2.3 g sodium) and protein intake to ≤1.0 g/kg may be reasonable goals, but such diets are not easy to achieve and maintain. Furthermore, protein restriction in infants and young children may be harmful and is not advised. (See  <a class="medical medical_patient" href="/d/html/4411.html" rel="external">"Patient education: Low-sodium diet (Beyond the Basics)"</a>.)</p><p>Although most children with AVP-R are underweight and relatively short during the first years of life, their height and weight become progressively normal during school-age years [<a href="#rid17">17</a>]. These growth observations could be related, in part, to limited caloric intake and decreased dietary solute during the first years of life.</p><p class="headingAnchor" id="H5"><span class="h2">Diuretics</span><span class="headingEndMark"> — </span>Thiazide diuretics in combination with a low-solute diet can diminish the degree of polyuria in patients with AVP-R [<a href="#rid2">2,18-20</a>]. The potassium-sparing diuretic <a class="drug drug_general" data-topicid="8550" href="/d/drug information/8550.html" rel="external">amiloride</a> also may be helpful, both by its additive effect with the thiazide diuretic [<a href="#rid21">21</a>] and, with reversible lithium-induced disease, by possibly allowing <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> to be continued (see below) [<a href="#rid22">22</a>].</p><p>A thiazide diuretic (such as <a class="drug drug_general" data-topicid="8529" href="/d/drug information/8529.html" rel="external">hydrochlorothiazide</a>, 25 mg once or twice daily) acts by inducing mild volume depletion. As little as a 1 to 1.5 kg weight loss can reduce the urine output by more than 50 percent (eg, from 10 L/day to below 3.5 L/day in a study of patients with AVP-R on a severely sodium-restricted diet [9 mEq/day]) [<a href="#rid18">18</a>].</p><p>This effect is presumably mediated by a hypovolemia-induced increase in proximal sodium and water reabsorption, thereby diminishing water delivery to the antidiuretic hormone (ADH)-sensitive sites in the collecting tubules and reducing the urine output. Diuretic therapy can lead to a variety of usually mild electrolyte complications. (See  <a class="medical medical_review" href="/d/html/2356.html" rel="external">"Time course of loop and thiazide diuretic-induced electrolyte complications"</a> and  <a class="medical medical_review" href="/d/html/2341.html" rel="external">"Causes of hypokalemia in adults", section on 'Diuretics'</a> and  <a class="medical medical_review" href="/d/html/2380.html" rel="external">"Diuretic-induced hyperuricemia and gout"</a>.)</p><p>The initial natriuresis and therefore the later antipolyuric response can be enhanced by combination therapy with <a class="drug drug_general" data-topicid="8550" href="/d/drug information/8550.html" rel="external">amiloride</a> (or other potassium-sparing diuretic) [<a href="#rid22">22</a>]. This regimen has an additional benefit since amiloride partially blocks the potassium wasting induced by the thiazide.</p><p><a class="drug drug_general" data-topicid="8550" href="/d/drug information/8550.html" rel="external">Amiloride</a> may be particularly beneficial in patients with reversible <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> nephrotoxicity, given its site and mechanism of action [<a href="#rid23">23,24</a>]. If amiloride is used, a small contraction of extracellular fluid volume may ensue, and it may be necessary to decrease the dose of lithium chronically administered and to measure plasma concentrations at frequent intervals until a new steady state is achieved. This drug closes the sodium channels in the luminal membrane of the collecting tubule cells [<a href="#rid25">25</a>]. These channels constitute the mechanism by which filtered lithium normally enters these cells and then interferes with their response to ADH [<a href="#rid21">21</a>]. The permeability for lithium of the epithelial sodium channel (ENaC) is 1.5- to 2-fold higher than that for sodium [<a href="#rid26">26</a>]. Whereas sodium is extruded from the interior of the cell to the blood compartment by the sodium pump (Na-K-ATPase) located at the basolateral membrane, lithium is a poor substrate for the sodium pump. As a consequence, toxic intracellular levels could build up quickly in all cells expressing ENaC at their plasma membrane and exposed to therapeutic concentrations of lithium (0.6 to 1.2 mmol/L) (see  <a class="medical medical_review" href="/d/html/2358.html" rel="external">"Renal toxicity of lithium"</a>). Glycogen synthase kinase 3 (GSK-3 beta) is inhibited by lithium and is probably the common molecular target for the primary and secondary toxic effects of lithium [<a href="#rid27">27,28</a>].</p><p><a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">Acetazolamide</a> monotherapy is as effective as the combination of <a class="drug drug_general" data-topicid="8529" href="/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> and <a class="drug drug_general" data-topicid="8550" href="/d/drug information/8550.html" rel="external">amiloride</a> in reducing polyuria in an animal model of lithium-induced AVP-R but has fewer side effects [<a href="#rid29">29</a>]. Human data are limited, although acetazolamide was used successfully in a patient with lithium-induced AVP-R and produced an increase in urine osmolality from 250 to 339 mosmol/kg H<sub>2</sub>O [<a href="#rid30">30</a>].</p><p>A loop diuretic, although also capable of inducing mild volume depletion, is not as likely to lower the urine output in AVP-R. These agents decrease sodium chloride reabsorption in the medullary thick ascending limb of the loop of Henle, thereby decreasing the accumulation of NaCl in the medullary interstitium that is essential for the production of a concentrated urine. Thus, a loop diuretic induces relative ADH resistance, an effect that is counterproductive in AVP-R.</p><p class="headingAnchor" id="H6"><span class="h2">Nonsteroidal antiinflammatory drugs</span><span class="headingEndMark"> — </span>The efficacy of NSAIDs in this setting is dependent upon inhibition of renal prostaglandin synthesis. In normal subjects, prostaglandins antagonize the action of ADH and NSAIDs increase concentrating ability [<a href="#rid31">31,32</a>]. If, for example, normal subjects are given a submaximal dose of ADH, the ensuing rise in urine osmolality can be increased by more than 200 mosmol/kg if the patient has been pretreated with an NSAID [<a href="#rid31">31</a>]. The net effect in patients with AVP-R may be a 25 to 50 percent reduction in urine output [<a href="#rid19">19,20,33</a>], a response that is partially additive to that of a thiazide diuretic [<a href="#rid20">20,22</a>].</p><p>This approach is particularly beneficial in patients with polyuria due to complex congenital polyuric-polydipsic Bartter-like syndromes, in whom prostaglandins appear to be pathogenetically important. (See  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations"</a>.)</p><p>Not all NSAIDs are equally effective in a given patient; as an example, <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> appears to have a greater effect than <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> [<a href="#rid19">19</a>]. A variety of complications may ensue with long-term use of NSAIDs. (See  <a class="medical medical_review" href="/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Exogenous ADH</span><span class="headingEndMark"> — </span>Most patients with <strong>nonhereditary</strong> AVP-R have partial rather than complete resistance to antidiuretic hormone (ADH, also known as arginine vasopressin [AVP]). It is therefore possible that attaining supraphysiologic hormone levels will increase the kidney effect of ADH to a clinically important degree. In some patients with AVP-R, exogenous ADH has been found to increase the urine osmolality by 40 to 45 percent, an effect that would be expected to produce a similar decline in urine volume [<a href="#rid23">23,34,35</a>].</p><p>In addition to nonhereditary AVP-R, some cases of hereditary AVP-R may respond to exogenous ADH.</p><p>Thus, <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> may be tried in patients who have persistent symptomatic polyuria after implementation of the above regimen. One case report of a patient with lithium-induced AVP-R suggested that benefit may be more likely if desmopressin is combined with an NSAID [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Experimental approaches</span><span class="headingEndMark"> — </span>Most patients with congenital X-linked AVP-R have defective V2 vasopressin receptors that are unable to properly fold intracellularly and, as a consequence, do not transfer to the cell surface where the receptors could respond to circulating vasopressin. Several new approaches to treatment of this disorder are being investigated: V2 receptor chaperones and V2 receptor bypass. (See  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes", section on 'Vasopressin V2 receptor gene mutations'</a>.)</p><p class="headingAnchor" id="H6612734"><span class="h3">V2 receptor chaperones</span><span class="headingEndMark"> — </span>In in vitro systems, the administration of selective, cell-permeable nonpeptide V2 and V1a receptor antagonists were able to rescue mutant V2 receptors, presumably acting intracellularly to promote proper folding and maturation [<a href="#rid37">37,38</a>]. This resulted in the expression of functional cell surface V2 receptors, suggesting that such a therapeutic approach may be effective in patients.</p><p>In a pilot study, a nonpeptide V1a receptor antagonist was administered to five men with AVP-R (each with one of three identified mutations in the <em>AVPR2</em> gene that codes for the V2 receptor) [<a href="#rid38">38</a>]. This resulted in an increase in urine osmolality from a mean of 100 to 150 mosmol/kg and reductions in urine volume from 12 to 8 L/day and in water intake from 11 to 7 L/day. Nonpeptide V2 agonists have also been demonstrated experimentally to rescue misfolded <em>AVPR2</em> mutations responsible for X-linked AVP-R [<a href="#rid39">39,40</a>].</p><p>Most mutations in aquaporin-2 (the vasopressin-sensitive water channel) that are associated with AVP-R result in proteins being retained in the intracellular space [<a href="#rid41">41</a>]. Research to find chaperone-like molecules to help direct these proteins to the cell surface is ongoing [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H6612741"><span class="h3">V2 receptor bypass</span><span class="headingEndMark"> — </span>The antidiuretic activity of the V2 receptor is mediated by the activation of a G protein-signaling cascade that leads to increased<strong> </strong>intracellular cyclic adenosine monophosphate (AMP) and the trafficking of aquaporin-2 to the cell membrane. The collecting duct also expresses two prostaglandin E2 receptors (EP2 and EP4) and a beta-3 adrenergic receptor; similar to the V2 receptor-signaling cascade, these receptors can increase intracellular cyclic AMP [<a href="#rid43">43-45</a>]. Prostaglandin E2 and beta-3<sub> </sub>adrenergic signaling through these receptors increases the apical membrane abundance and phosphorylation of aquaporin-2.</p><p>Thus, stimulation of prostaglandin E2 receptors EP2 and EP4, and stimulation of beta-3 adrenergic receptors, may be a way of bypassing the need for V2 receptor signaling. In a mouse model of X-linked AVP-R, for example, ONO-AE1-329, a selective agonist of the EP4 prostaglandin E2 receptor in the collecting tubule cells, increased urine osmolality from 150 to 500 mosmol/kg H<sub>2</sub>O [<a href="#rid46">46</a>]. In addition, a beta-3 adrenergic receptor agonist increased urine osmolality in a murine model of AVP-R from 150 to 250 mosmol/kg H<sub>2</sub>O [<a href="#rid47">47</a>].</p><p>The phosphodiesterase inhibitor, <a class="drug drug_general" data-topicid="9643" href="/d/drug information/9643.html" rel="external">sildenafil</a>, has also shown similar effects in a single case report, improving the urine osmolality in a patient with X-linked AVP-R [<a href="#rid48">48</a>]. <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> may also transiently increase urine osmolality in rodent models, although there is a rapid return to basal values [<a href="#rid49">49</a>]. <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> may have similar effects [<a href="#rid50">50</a>].</p><p>Adenosine monophosphate-activated protein kinase (AMPK) has been shown to phosphorylate aquaporin-2 and increase the urine concentration in animal models of AVP-R [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H4206267619"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109733.html" rel="external">"Society guideline links: Fluid and electrolyte disorders in adults"</a>.)</p><p class="headingAnchor" id="H169870927"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/17196.html" rel="external">"Patient education: Arginine vasopressin disorders (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H9"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Arginine vasopressin resistance (AVP-R, previously known as nephrogenic diabetes insipidus) results from partial or complete resistance of the kidney to the effects of antidiuretic hormone (ADH, also known as arginine vasopressin [AVP]). In adults, a concentrating defect severe enough to produce polyuria due to AVP-R is most often due to chronic <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> use or hypercalcemia and less frequently to other conditions that impair tubular function, such as Sjögren's disease. In infants, congenital AVP-R is most common. (See  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>.)</p><p>If a cause can be identified, we recommend correcting the underlying disorder (eg, hypercalcemia) or discontinuing the offending drug, if feasible. Lithium-induced AVP-R may be irreversible if tubular injury is severe and there is a marked concentrating defect. (See  <a class="medical medical_review" href="/d/html/2358.html" rel="external">"Renal toxicity of lithium"</a>.)</p><p>There are usually no adverse medical effects of polyuria, although, as noted above, the functional hydronephrosis in congenital AVP-R rarely leads to significant kidney injury [<a href="#rid10">10</a>]. As a result, the only indication for therapy in adults is to relieve the patient's symptoms.</p><p class="headingAnchor" id="H10"><span class="h2">Initial therapy</span><span class="headingEndMark"> — </span>Therapy of the polyuria in AVP-R consists of the following sequential approach:</p><p class="bulletIndent1"><span class="glyph">●</span>All adult patients should be instructed to take a low-sodium, low-protein diet, as tolerated, and all infants and young children should be provided a low-sodium diet. The reduction in urine output will be directly proportional to the fall in solute excretion. As a result, the efficacy of solute restriction will depend directly upon patient compliance. (See <a class="local">'Decreased dietary solute'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In all patients who have significant polyuria, we recommend frequent and "double-voiding" to avoid bladder dilatation and dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In all children, and in adults with symptomatic polyuria persisting despite a low-solute diet, we recommend starting a thiazide diuretic (eg, <a class="drug drug_general" data-topicid="8529" href="/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> 25 mg once daily to a usual maximum of 25 mg twice daily in adults and appropriate dosing in children) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Diuretics'</a> above.)</p><p></p><p class="bulletIndent1">The preferred initial therapy is similar in children with polyuria due to complex congenital polyuric-polydipsic Bartter-like syndromes, in whom we recommend nonsteroidal antiinflammatory drugs (NSAIDs) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Nonsteroidal antiinflammatory drugs'</a> above and  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest adding <a class="drug drug_general" data-topicid="8550" href="/d/drug information/8550.html" rel="external">amiloride</a> if the urine output is insufficiently reduced (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We recommend amiloride as part of primary therapy to prevent progression of, or possibly improve, lithium-induced AVP-R in patients in whom <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> is continued (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Diuretics'</a> above.)</p><p></p><p>In patients taking <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, a low-sodium diet and the use of thiazide and/or <a class="drug drug_general" data-topicid="8550" href="/d/drug information/8550.html" rel="external">amiloride</a> may increase the plasma level of lithium. Thus, frequent measurements of lithium and a decrease in the daily lithium dose may be necessary when initiating such treatments.</p><p class="bulletIndent1"><span class="glyph">●</span>If symptomatic polyuria persists, we suggest adding <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> if there are no contraindications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Nonsteroidal antiinflammatory drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who cannot be treated with NSAIDs or who have persistent symptomatic polyuria after the addition of NSAIDs, we suggest a trial of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Exogenous ADH'</a> above.)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Hereditary disease</span><span class="headingEndMark"> — </span>There are special considerations in the management of hereditary AVP-R, particularly in infants and young children (see <a class="local">'Special considerations in hereditary disease'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>In infants and very young children, we recommend offering water every two hours, with the goal of avoiding severe dehydration and hypernatremia (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). If gastroesophageal reflux becomes problematic, we recommend appropriate management. (See  <a class="medical medical_review" href="/d/html/5900.html" rel="external">"Management of gastroesophageal reflux disease in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In all children, we recommend implementation of measures to decrease urine flow, as discussed above, and frequent and "double voiding," with the goal of avoiding dilatation of the urinary tract and bladder (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). We suggest continuing these preventive measures to avoid dilatation of the urinary tract in adulthood.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Arima H, Cheetham T, Christ-Crain M, et al. Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus. J Clin Endocrinol Metab 2022; 108:1.</a></li><li class="breakAll">Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.754,782.</li><li><a class="nounderline abstract_t">Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 2005; 16:2836.</a></li><li><a class="nounderline abstract_t">Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol 2015; 11:576.</a></li><li><a class="nounderline abstract_t">Sharma S, Ashton E, Iancu D, et al. Long-term outcome in inherited nephrogenic diabetes insipidus. Clin Kidney J 2019; 12:180.</a></li><li><a class="nounderline abstract_t">Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987; 10:329.</a></li><li><a class="nounderline abstract_t">Ulinski T, Grapin C, Forin V, et al. Severe bladder dysfunction in a family with ADH receptor gene mutation responsible for X-linked nephrogenic diabetes insipidus. Nephrol Dial Transplant 2004; 19:2928.</a></li><li><a class="nounderline abstract_t">Shalev H, Romanovsky I, Knoers NV, et al. Bladder function impairment in aquaporin-2 defective nephrogenic diabetes insipidus. Nephrol Dial Transplant 2004; 19:608.</a></li><li><a class="nounderline abstract_t">Uribarri J, Kaskas M. Hereditary nephrogenic diabetes insipidus and bilateral nonobstructive hydronephrosis. Nephron 1993; 65:346.</a></li><li><a class="nounderline abstract_t">Streitz JM Jr, Streitz JM. Polyuric urinary tract dilatation with renal damage. J Urol 1988; 139:784.</a></li><li><a class="nounderline abstract_t">Zender HO, Ruedin P, Moser F, et al. Traumatic rupture of the urinary tract in a patient presenting nephrogenic diabetes insipidus associated with hydronephrosis and chronic renal failure: case report and review of the literature. Clin Nephrol 1992; 38:196.</a></li><li><a class="nounderline abstract_t">Higuchi A, Kawamura T, Nakai H, Hasegawa Y. Infrequent voiding in nephrogenic diabetes insipidus as a cause of renal failure. Pediatr Int 2002; 44:540.</a></li><li><a class="nounderline abstract_t">Caletti MG, Balestracci A, Di Pinto D. Pre- and post-treatment urinary tract findings in children with nephrogenic diabetes insipidus. Pediatr Nephrol 2014; 29:487.</a></li><li class="breakAll">Bockenhauer D. Diabetes insipidus. In: Comprehensive Pediatric Nephrology, 1st ed, Geary DF, Schaefer F (Eds), Mosby Elsevier, Philadelphia 2008. p.489.</li><li><a class="nounderline abstract_t">Bockenhauer D, Bichet DG. Nephrogenic diabetes insipidus. Curr Opin Pediatr 2017; 29:199.</a></li><li><a class="nounderline abstract_t">Wesche D, Deen PM, Knoers NV. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr Nephrol 2012; 27:2183.</a></li><li><a class="nounderline abstract_t">van Lieburg AF, Knoers NV, Monnens LA. Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1999; 10:1958.</a></li><li><a class="nounderline abstract_t">Earley LE, Orloff J. THE MECHANISM OF ANTIDIURESIS ASSOCIATED WITH THE ADMINISTRATION OF HYDROCHLOROTHIAZIDE TO PATIENTS WITH VASOPRESSIN-RESISTANT DIABETES INSIPIDUS. J Clin Invest 1962; 41:1988.</a></li><li><a class="nounderline abstract_t">Libber S, Harrison H, Spector D. Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors. J Pediatr 1986; 108:305.</a></li><li><a class="nounderline abstract_t">Monnens L, Jonkman A, Thomas C. Response to indomethacin and hydrochlorothiazide in nephrogenic diabetes insipidus. Clin Sci (Lond) 1984; 66:709.</a></li><li><a class="nounderline abstract_t">Batlle DC, von Riotte AB, Gaviria M, Grupp M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 1985; 312:408.</a></li><li><a class="nounderline abstract_t">Knoers N, Monnens LA. Amiloride-hydrochlorothiazide versus indomethacin-hydrochlorothiazide in the treatment of nephrogenic diabetes insipidus. J Pediatr 1990; 117:499.</a></li><li><a class="nounderline abstract_t">Bedford JJ, Weggery S, Ellis G, et al. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol 2008; 3:1324.</a></li><li><a class="nounderline abstract_t">Christensen BM, Zuber AM, Loffing J, et al. alphaENaC-mediated lithium absorption promotes nephrogenic diabetes insipidus. J Am Soc Nephrol 2011; 22:253.</a></li><li><a class="nounderline abstract_t">Kortenoeven ML, Li Y, Shaw S, et al. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int 2009; 76:44.</a></li><li><a class="nounderline abstract_t">Grünfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5:270.</a></li><li><a class="nounderline abstract_t">O'Brien WT, Harper AD, Jové F, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004; 24:6791.</a></li><li><a class="nounderline abstract_t">Alsady M, Baumgarten R, Deen PM, de Groot T. Lithium in the Kidney: Friend and Foe? J Am Soc Nephrol 2016; 27:1587.</a></li><li><a class="nounderline abstract_t">de Groot T, Sinke AP, Kortenoeven ML, et al. Acetazolamide Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus. J Am Soc Nephrol 2016; 27:2082.</a></li><li><a class="nounderline abstract_t">Gordon CE, Vantzelfde S, Francis JM. Acetazolamide in Lithium-Induced Nephrogenic Diabetes Insipidus. N Engl J Med 2016; 375:2008.</a></li><li><a class="nounderline abstract_t">Berl T, Raz A, Wald H, et al. Prostaglandin synthesis inhibition and the action of vasopressin: studies in man and rat. Am J Physiol 1977; 232:F529.</a></li><li><a class="nounderline abstract_t">Stokes JB. Integrated actions of renal medullary prostaglandins in the control of water excretion. Am J Physiol 1981; 240:F471.</a></li><li><a class="nounderline abstract_t">Allen HM, Jackson RL, Winchester MD, et al. Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus. Arch Intern Med 1989; 149:1123.</a></li><li><a class="nounderline abstract_t">Miller M, Dalakos T, Moses AM, et al. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med 1970; 73:721.</a></li><li><a class="nounderline abstract_t">Zerbe RL, Robertson GL. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. N Engl J Med 1981; 305:1539.</a></li><li><a class="nounderline abstract_t">Stasior DS, Kikeri D, Duel B, Seifter JL. Nephrogenic diabetes insipidus responsive to indomethacin plus dDAVP. N Engl J Med 1991; 324:850.</a></li><li><a class="nounderline abstract_t">Morello JP, Salahpour A, Laperrière A, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000; 105:887.</a></li><li><a class="nounderline abstract_t">Bernier V, Morello JP, Zarruk A, et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2006; 17:232.</a></li><li><a class="nounderline abstract_t">Robben JH, Kortenoeven ML, Sze M, et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci U S A 2009; 106:12195.</a></li><li><a class="nounderline abstract_t">Jean-Alphonse F, Perkovska S, Frantz MC, et al. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 2009; 20:2190.</a></li><li><a class="nounderline abstract_t">Sasaki S. Nephrogenic diabetes insipidus: update of genetic and clinical aspects. Nephrol Dial Transplant 2004; 19:1351.</a></li><li><a class="nounderline abstract_t">Yang B, Zhao D, Verkman AS. Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation. FASEB J 2009; 23:503.</a></li><li><a class="nounderline abstract_t">Olesen ET, Rützler MR, Moeller HB, et al. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc Natl Acad Sci U S A 2011; 108:12949.</a></li><li><a class="nounderline abstract_t">Gao M, Cao R, Du S, et al. Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts. Proc Natl Acad Sci U S A 2015; 112:8397.</a></li><li><a class="nounderline abstract_t">Procino G, Carmosino M, Milano S, et al. β3 adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function. Kidney Int 2016; 90:555.</a></li><li><a class="nounderline abstract_t">Li JH, Chou CL, Li B, et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J Clin Invest 2009; 119:3115.</a></li><li><a class="nounderline abstract_t">Bichet DG. β3-Adrenoreceptors in the thick ascending limb of Henle and in principal cells of the collecting duct work to concentrate urine. Kidney Int 2016; 90:471.</a></li><li><a class="nounderline abstract_t">Assadi F, Sharbaf FG. Sildenafil for the Treatment of Congenital Nephrogenic Diabetes Insipidus. Am J Nephrol 2015; 42:65.</a></li><li><a class="nounderline abstract_t">Efe O, Klein JD, LaRocque LM, et al. Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus. JCI Insight 2016; 1.</a></li><li><a class="nounderline abstract_t">Vukićević T, Hinze C, Baltzer S, et al. Fluconazole Increases Osmotic Water Transport in Renal Collecting Duct through Effects on Aquaporin-2 Trafficking. J Am Soc Nephrol 2019; 30:795.</a></li><li><a class="nounderline abstract_t">Klein JD, Khanna I, Pillarisetti R, et al. An AMPK activator as a therapeutic option for congenital nephrogenic diabetes insipidus. JCI Insight 2021; 6.</a></li></ol></div><div id="topicVersionRevision">Topic 2382 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36355385" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36355385" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16093448" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Molecular biology of hereditary diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26077742" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30976394" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term outcome in inherited nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3314489" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496575" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Severe bladder dysfunction in a family with ADH receptor gene mutation responsible for X-linked nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767016" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bladder function impairment in aquaporin-2 defective nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8289981" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hereditary nephrogenic diabetes insipidus and bilateral nonobstructive hydronephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3352042" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Polyuric urinary tract dilatation with renal damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1424306" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Traumatic rupture of the urinary tract in a patient presenting nephrogenic diabetes insipidus associated with hydronephrosis and chronic renal failure: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12225559" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Infrequent voiding in nephrogenic diabetes insipidus as a cause of renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24337364" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pre- and post-treatment urinary tract findings in children with nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24337364" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pre- and post-treatment urinary tract findings in children with nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28134709" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22427315" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Congenital nephrogenic diabetes insipidus: the current state of affairs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10477148" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16695887" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : THE MECHANISM OF ANTIDIURESIS ASSOCIATED WITH THE ADMINISTRATION OF HYDROCHLOROTHIAZIDE TO PATIENTS WITH VASOPRESSIN-RESISTANT DIABETES INSIPIDUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3080575" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6723207" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Response to indomethacin and hydrochlorothiazide in nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3969096" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2391611" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Amiloride-hydrochlorothiazide versus indomethacin-hydrochlorothiazide in the treatment of nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18596116" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21051735" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : alphaENaC-mediated lithium absorption promotes nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19367330" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384328" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lithium nephrotoxicity revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15282284" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26577775" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lithium in the Kidney: Friend and Foe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26574046" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acetazolamide Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959610" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acetazolamide in Lithium-Induced Nephrogenic Diabetes Insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/195476" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prostaglandin synthesis inhibition and the action of vasopressin: studies in man and rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7018256" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Integrated actions of renal medullary prostaglandins in the control of water excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2719505" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5476203" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Recognition of partial defects in antidiuretic hormone secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7311993" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1997862" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nephrogenic diabetes insipidus responsive to indomethacin plus dDAVP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10749568" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319185" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587238" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19729439" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15004257" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Nephrogenic diabetes insipidus: update of genetic and clinical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18854434" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768374" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26100911" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27206969" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : β3 adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19729836" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521107" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : β3-Adrenoreceptors in the thick ascending limb of Henle and in principal cells of the collecting duct work to concentrate urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26337818" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sildenafil for the Treatment of Congenital Nephrogenic Diabetes Insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27478876" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30988011" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fluconazole Increases Osmotic Water Transport in Renal Collecting Duct through Effects on Aquaporin-2 Trafficking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33724959" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : An AMPK activator as a therapeutic option for congenital nephrogenic diabetes insipidus.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
